Non-invasive testing and risk-stratification in patients with MASLD
European Journal of Internal Medicine · 2024-04 · 122 · 11-19
DOI: 10.1016/j.ejim.2024.01.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2024-04. Verfasst von Mirko Zoncapè und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK; Liver Unit,…. Hauptthemen laut MEDLINE: Metabolic Diseases, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 109 Literaturangaben.
Abstract (Originalsprache)
The development and validation of non-invasive fibrosis tests (NITs) has changed clinical practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent liver disease in western countries, with up to a third of the unselected adult population affected. In this article, we review the use of NITs in the diagnosis and staging of MASLD. We discuss their use in the diagnosis of steatosis, steatohepatitis and fibrosis and critically evaluate recently published data. These NITs include a variety of approaches, such as serum markers like FIB-4, pro-C3 and ELF, imaging techniques like Fibroscan® and MRE, and combined scores like Agile 3+ and Agile 4, offering a range of options for healthcare providers. Furthermore, these non-invasive tests also serve as valuable prognostic tools, allowing for better risk assessment and improved patient management, particularly in predicting liver-related events and overall mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK; Liver Unit, Department of Medicine, University of Verona and Azienda Ospedaliera…
- Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK; Medical and Surgical Sciences Department, Fondazione Policlinico Universitario A.…
- Sheila Sherlock Liver Unit, Royal Free Hospital, London, UK; UCL Institute for Liver and Digestive Health, University College London, UK. Electronic address: e.tsochatzis@ucl.ac.uk.
Zitieren
APA
Zoncapè, M., Liguori, A., & Tsochatzis, E. A. (2024). Non-invasive testing and risk-stratification in patients with MASLD. European Journal of Internal Medicine, 122, 11-19. https://doi.org/10.1016/j.ejim.2024.01.013
Vancouver
Zoncapè M, Liguori A, Tsochatzis EA. Non-invasive testing and risk-stratification in patients with MASLD. European Journal of Internal Medicine. 2024;122:11-19. doi:10.1016/j.ejim.2024.01.013
BibTeX
@article{Zoncap2024,
author = {Zoncapè, Mirko and Liguori, Antonio and Tsochatzis, Emmanuel A},
title = {Non-invasive testing and risk-stratification in patients with MASLD},
journal = {European Journal of Internal Medicine},
year = {2024},
volume = {122},
pages = {11--19},
doi = {10.1016/j.ejim.2024.01.013}
}
EUVIMED